The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FIH phase I dose escalation study of FN1501, an investigational FLT-3 inhibitor with multiple targets in patients with relapsed or refractory solid tumors and acute myeloid leukemia.
 
Gary Edward Richardson
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Fosun Pharma (Inst); Merck (Inst); Novotech (Inst); Pfizer (Inst); Roche/Genentech (Inst); Shanghai Henlius Biotech (Inst); Suzhou Alphamab (Inst); Takeda (Inst)
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer
 
Viviana Bozon
Employment - Fosun Pharma
Stock and Other Ownership Interests - Array Biopharma; Pfizer; Takeda
Patents, Royalties, Other Intellectual Property - Takeda
 
Ai-Min Hui
Employment - Fosun Pharma
 
Stephen K. Williamson
Research Funding - Acceleron Pharma (Inst); Aleon Pharma (Inst); Astellas Pharma (Inst); Bayer Health (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Merck Serono (Inst); Nektar (Inst); Novartis (Inst); Pharmacyclics (Inst); Regeneron (Inst); Rogosin Institute (Inst); Sanofi (Inst); Seagen (Inst); Sotio (Inst)